GB9205320D0 - Anti-tumour compounds - Google Patents

Anti-tumour compounds

Info

Publication number
GB9205320D0
GB9205320D0 GB929205320A GB9205320A GB9205320D0 GB 9205320 D0 GB9205320 D0 GB 9205320D0 GB 929205320 A GB929205320 A GB 929205320A GB 9205320 A GB9205320 A GB 9205320A GB 9205320 D0 GB9205320 D0 GB 9205320D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
quinazoline
pharmaceutically
hydrogen
tumour compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB929205320A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Institute of Cancer Research: Royal Cancer Hospital
Imperial Chemical Industries Ltd
Original Assignee
The Institute of Cancer Research: Royal Cancer Hospital
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute of Cancer Research: Royal Cancer Hospital, Imperial Chemical Industries Ltd filed Critical The Institute of Cancer Research: Royal Cancer Hospital
Priority to GB929205320A priority Critical patent/GB9205320D0/en
Publication of GB9205320D0 publication Critical patent/GB9205320D0/en
Priority to AU33782/93A priority patent/AU659277B2/en
Priority to ZA931447A priority patent/ZA931447B/xx
Priority to CA002090942A priority patent/CA2090942C/en
Priority to IL104984A priority patent/IL104984A/en
Priority to CZ93362A priority patent/CZ281811B6/cs
Priority to MX9301281A priority patent/MX9301281A/es
Priority to EP93301780A priority patent/EP0562734B1/en
Priority to DE69301048T priority patent/DE69301048T2/de
Priority to ES93301780T priority patent/ES2081178T3/es
Priority to DK93301780.8T priority patent/DK0562734T3/da
Priority to GB9304807A priority patent/GB2264946B/en
Priority to AT93301780T priority patent/ATE131823T1/de
Priority to US08/028,158 priority patent/US5955463A/en
Priority to FI931067A priority patent/FI108793B/fi
Priority to RU93004793A priority patent/RU2111209C1/ru
Priority to KR1019930003536A priority patent/KR100221011B1/ko
Priority to NO930881A priority patent/NO301543B1/no
Priority to NZ247122A priority patent/NZ247122A/xx
Priority to JP05052593A priority patent/JP3160111B2/ja
Priority to TW082101928A priority patent/TW223635B/zh
Priority to HU95P/P00202P priority patent/HU211127A9/hu
Priority to GR950403484T priority patent/GR3018501T3/el
Priority to HK21297A priority patent/HK21297A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Dental Preparations (AREA)
  • Golf Clubs (AREA)
GB929205320A 1992-03-11 1992-03-11 Anti-tumour compounds Pending GB9205320D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GB929205320A GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds
AU33782/93A AU659277B2 (en) 1992-03-11 1993-02-25 Anti-tumour compounds
ZA931447A ZA931447B (en) 1992-03-11 1993-03-01 Anti-tumour compounds.
CA002090942A CA2090942C (en) 1992-03-11 1993-03-03 Anti-tumour compounds containing quinazoline and tetrazole rings
IL104984A IL104984A (en) 1992-03-11 1993-03-08 £n-(4-oxo-3, 4-dihydroquinazolin- 6-ylmethyl)-n-alkylamino| benzamido-4-(tetrazol-5-yl) butyric acid derivatives, processes for their preparation and pharmaceutical compositions containing them
CZ93362A CZ281811B6 (cs) 1992-03-11 1993-03-08 Protinádorové účinné sloučeniny
US08/028,158 US5955463A (en) 1992-03-11 1993-03-09 Quinazoline thymidylate synthase inhibitors
DK93301780.8T DK0562734T3 (da) 1992-03-11 1993-03-09 Antitumorforbindelser indeholdende quinazolin- og tetrazolringe
EP93301780A EP0562734B1 (en) 1992-03-11 1993-03-09 Anti-tumour compounds containing quinazoline and tetrazole rings
DE69301048T DE69301048T2 (de) 1992-03-11 1993-03-09 Verbindungen, die Quinazoline und Tetrazolring enthalten, als Antitumorverbindungen
ES93301780T ES2081178T3 (es) 1992-03-11 1993-03-09 Compuestos anti-tumorales que contienen anillos quinazolina y tetrazol.
MX9301281A MX9301281A (es) 1992-03-11 1993-03-09 Compuestos contra tumores.
GB9304807A GB2264946B (en) 1992-03-11 1993-03-09 Anti-tumour compounds
AT93301780T ATE131823T1 (de) 1992-03-11 1993-03-09 Verbindungen, die quinazoline und tetrazolring enthalten, als antitumorverbindungen
NO930881A NO301543B1 (no) 1992-03-11 1993-03-10 2-£4-(kinazolinylmetylamino)benzamido|-4-(tetrazolyl)smörsyrederivater med anti-tumor-aktivitet
RU93004793A RU2111209C1 (ru) 1992-03-11 1993-03-10 Производные хиназолина, способ их получения и фармацевтическая композиция на их основе
FI931067A FI108793B (fi) 1992-03-11 1993-03-10 Menetelmä terapeuttisesti käyttökelpoisten kinatsoliinijohdannaisten valmistamiseksi
KR1019930003536A KR100221011B1 (ko) 1992-03-11 1993-03-10 항-종양 화합물, 이의 제조 방법 및 이를 함유하는 약학 조성물
NZ247122A NZ247122A (en) 1992-03-11 1993-03-11 Tetrazole-quinazolin-4-one derivatives and medicaments
JP05052593A JP3160111B2 (ja) 1992-03-11 1993-03-11 キナゾリン誘導体、その製造法および該化合物を含有する、温血動物中に抗腫瘍作用を生じさせるための医薬調剤
TW082101928A TW223635B (cg-RX-API-DMAC7.html) 1992-03-11 1993-03-16
HU95P/P00202P HU211127A9 (en) 1992-03-11 1995-06-14 Anti-tumour compounds
GR950403484T GR3018501T3 (en) 1992-03-11 1995-12-21 Anti-tumour compounds containing quinazoline and tetrazole rings
HK21297A HK21297A (en) 1992-03-11 1997-02-27 Anti-tumour compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929205320A GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds

Publications (1)

Publication Number Publication Date
GB9205320D0 true GB9205320D0 (en) 1992-04-22

Family

ID=10711936

Family Applications (2)

Application Number Title Priority Date Filing Date
GB929205320A Pending GB9205320D0 (en) 1992-03-11 1992-03-11 Anti-tumour compounds
GB9304807A Expired - Fee Related GB2264946B (en) 1992-03-11 1993-03-09 Anti-tumour compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB9304807A Expired - Fee Related GB2264946B (en) 1992-03-11 1993-03-09 Anti-tumour compounds

Country Status (22)

Country Link
US (1) US5955463A (cg-RX-API-DMAC7.html)
EP (1) EP0562734B1 (cg-RX-API-DMAC7.html)
JP (1) JP3160111B2 (cg-RX-API-DMAC7.html)
KR (1) KR100221011B1 (cg-RX-API-DMAC7.html)
AT (1) ATE131823T1 (cg-RX-API-DMAC7.html)
AU (1) AU659277B2 (cg-RX-API-DMAC7.html)
CA (1) CA2090942C (cg-RX-API-DMAC7.html)
CZ (1) CZ281811B6 (cg-RX-API-DMAC7.html)
DE (1) DE69301048T2 (cg-RX-API-DMAC7.html)
DK (1) DK0562734T3 (cg-RX-API-DMAC7.html)
ES (1) ES2081178T3 (cg-RX-API-DMAC7.html)
FI (1) FI108793B (cg-RX-API-DMAC7.html)
GB (2) GB9205320D0 (cg-RX-API-DMAC7.html)
GR (1) GR3018501T3 (cg-RX-API-DMAC7.html)
HK (1) HK21297A (cg-RX-API-DMAC7.html)
HU (1) HU211127A9 (cg-RX-API-DMAC7.html)
IL (1) IL104984A (cg-RX-API-DMAC7.html)
NO (1) NO301543B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ247122A (cg-RX-API-DMAC7.html)
RU (1) RU2111209C1 (cg-RX-API-DMAC7.html)
TW (1) TW223635B (cg-RX-API-DMAC7.html)
ZA (1) ZA931447B (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
JPH11507052A (ja) * 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US7119174B2 (en) 1995-12-18 2006-10-10 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6818440B2 (en) 1997-04-28 2004-11-16 Sugen, Inc. Diagnosis and treatment of alk-7 related disorders
US6228641B1 (en) 1997-05-20 2001-05-08 Sugen, Inc. Diagnosis and treatment of PTP04 related disorders
US6342593B1 (en) 1997-06-11 2002-01-29 Sugen, Inc. Diagnosis and treatment of ALP related disorders
US7115710B2 (en) 1997-06-11 2006-10-03 Sugen, Inc. Diagnosis and treatment of PTP related disorders
US6388063B1 (en) 1997-06-18 2002-05-14 Sugen, Inc. Diagnosis and treatment of SAD related disorders
US6495353B1 (en) 1998-01-21 2002-12-17 Sugen, Inc. Human orthologues of wart
AU3642499A (en) 1998-04-14 1999-11-01 Sugen, Inc. Ste20-related protein kinases
US6235213B1 (en) * 1998-05-18 2001-05-22 Micron Technology, Inc. Etching methods, methods of removing portions of material, and methods of forming silicon nitride spacers
US6861442B1 (en) 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
RU2256654C2 (ru) * 1999-01-22 2005-07-20 Кирин Бир Кабусики Кайся Хинолиновые и хиназолиновые производные
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
EP1222273A2 (en) 1999-10-22 2002-07-17 PHARMACIA & UPJOHN COMPANY Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
DE60134224D1 (de) 2001-08-10 2008-07-10 Ford Global Tech Inc Ansaugkrümmer
KR100983962B1 (ko) 2001-08-31 2010-09-27 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[g]퀴나졸린 화합물
ES2373644T3 (es) 2001-08-31 2012-02-07 Btg International Limited Uso de derivados de ciclopenta[g]quinazolina para el tratamiento del c�?ncer.
RU2350618C2 (ru) * 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0317631D0 (en) * 2003-07-28 2003-08-27 Btg Int Ltd Synthetic method
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005080356A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
EP1962903B1 (en) 2005-12-15 2013-03-13 MedImmune Limited Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (en) * 1979-12-19 1984-10-17 National Research Development Corporation Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
JPS5692876A (en) * 1979-12-19 1981-07-27 Nat Res Dev Anticancerous quinazoline derivative
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8607683D0 (en) * 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4725687A (en) * 1986-04-28 1988-02-16 Southern Research Institute 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
US4999424A (en) * 1988-11-10 1991-03-12 The Pennsylvania State University GAR transformylase inhibitor
US5252573A (en) * 1988-12-15 1993-10-12 Imperial Chemical Industries Plc Anti-tumor agents
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
AU640016B2 (en) * 1990-05-30 1993-08-12 Imperial Chemical Industries Plc Hydroquinazoline derivatives
US5145854A (en) * 1991-11-27 1992-09-08 Nair Madhavan G 1-formyl-5,8,10-trideazafolates

Also Published As

Publication number Publication date
GR3018501T3 (en) 1996-03-31
GB2264946A (en) 1993-09-15
DE69301048D1 (de) 1996-02-01
DE69301048T2 (de) 1996-05-15
FI108793B (fi) 2002-03-28
CA2090942C (en) 2000-02-08
ES2081178T3 (es) 1996-02-16
KR100221011B1 (ko) 1999-09-15
RU2111209C1 (ru) 1998-05-20
ZA931447B (en) 1993-09-13
FI931067A0 (fi) 1993-03-10
AU3378293A (en) 1993-09-16
IL104984A (en) 1998-01-04
GB2264946B (en) 1995-05-17
AU659277B2 (en) 1995-05-11
IL104984A0 (en) 1993-07-08
EP0562734B1 (en) 1995-12-20
NO930881L (no) 1993-09-13
NZ247122A (en) 1995-07-26
NO301543B1 (no) 1997-11-10
JPH06279438A (ja) 1994-10-04
CA2090942A1 (en) 1993-09-12
HU211127A9 (en) 1995-10-30
JP3160111B2 (ja) 2001-04-23
DK0562734T3 (da) 1996-05-06
FI931067L (fi) 1993-09-12
EP0562734A1 (en) 1993-09-29
NO930881D0 (no) 1993-03-10
TW223635B (cg-RX-API-DMAC7.html) 1994-05-11
CZ281811B6 (cs) 1997-02-12
ATE131823T1 (de) 1996-01-15
HK21297A (en) 1997-02-27
CZ36293A3 (en) 1994-01-19
US5955463A (en) 1999-09-21
KR930019667A (ko) 1993-10-18
GB9304807D0 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
GB2264946B (en) Anti-tumour compounds
IL120266A (en) Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
AU679859B2 (en) Novel compound, process for producing the same, and antitumor agent
MY129970A (en) Hypolipidaemic compounds
ATE119774T1 (de) Imidazopyridinderivate und ihre verwendung.
AU1282495A (en) Anthranilic acid derivative
DE3572978D1 (en) Piperazine compound as paf-antagonist
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
HU906360D0 (en) Process for producing quinoline derivatives and pharmaceutical preparatives containing such compounds
HUT70506A (en) Pyridinecarboximidamide compounds, pharmaceutical compositions containing them and process for producing them
AU1507888A (en) New bicyclic compounds, processes for preparation thereof and pharmaceutical composition comprising the same
DE69129790D1 (de) 5-Amino-5,6,7,8-Tetrahydrochinoline und verwandte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
HU901377D0 (en) Process for preparation of carbamates
GR3019145T3 (en) Fungicidal furanone derivatives
ATE189813T1 (de) Prostaglandin-i-analoga
GR3004321T3 (cg-RX-API-DMAC7.html)
TW258661B (cg-RX-API-DMAC7.html)
GR3001003T3 (en) Novel pregnane derivatives, processes for their preparaton and pharmaceutical compositions containing same
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.

Legal Events

Date Code Title Description
730A Proceeding under section 30 patents act 1977